What is the market cap of Krebs Biochemicals & Ind?

As of 23/06/2026, the market cap of Krebs Biochemicals & Ind stands at ₹141.10 Cr.

What is the PE and PB ratio of Krebs Biochemicals & Ind?

The PE and PB ratios of Krebs Biochemicals & Ind is -8.16 ratio and -75.48 ratio as of 23/06/2026.

What is the 52 week high and low of Krebs Biochemicals & Ind?

The 52 week high and low of Krebs Biochemicals & Ind is ₹91.9 and ₹38.33 as of 23/06/2026.

How can I buy Krebs Biochemicals & Ind share?

You can easily buy Krebs Biochemicals & Ind shares on the Bajaj Broking platform by opening a Demat account and verifying your KYC documents online. There are no account opening charges for a Demat account with Bajaj Broking.

What determines a company’s share price?

A company’s share price is determined by supply and demand dynamics in the stock market. Factors influencing it include the company’s financial performance, earnings growth, revenue, and profitability, as well as broader economic conditions, market sentiment, and investor perception. Other determinants include sector trends, government policies, interest rates, and global events. Positive news or growth prospects can drive demand and raise the share price, while negative developments can push it lower. Analysts’ recommendations, institutional buying or selling, and technical factors such as trading volume also influence price movements. Ultimately, the share price reflects the market’s collective view of a company’s current and future value.

What is the “last sale,” “bid,” and “ask” price of Krebs Biochemicals & Ind?

The “last sale” is the most recent price at which a stock, like Krebs Biochemicals & Ind , was traded. The “bid” price represents the highest price buyers are willing to pay, while the “ask” price is the lowest price sellers are ready to accept. The difference between the bid and ask is known as the spread. Monitoring these prices helps investors understand market sentiment and liquidity. For example, a narrow spread indicates high liquidity and active trading, while a wide spread may suggest lower activity or higher volatility. These metrics are crucial for executing timely buy or sell orders in the stock market.

How to read share price charts for Krebs Biochemicals & Ind?

Share price charts display the historical price movement of Krebs Biochemicals & Ind , helping investors analyse trends, patterns, and potential entry or exit points. Charts typically show candlestick patterns, line graphs, or bar charts, representing open, high, low, and close prices. Key indicators include moving averages, support and resistance levels, and trading volume. Candlestick patterns can reveal bullish or bearish trends, while volume confirms the strength of price movements. Investors can use charts for technical analysis to assess momentum, predict short-term fluctuations, or complement fundamental analysis for long-term decisions. Understanding trends over daily, weekly, or monthly periods helps in making informed trading and investment choices.

What is volatility, and how does it affect share price movement for Krebs Biochemicals & Ind?

Volatility measures the degree of price fluctuations of a stock over time. High volatility indicates that Krebs Biochemicals & Ind share price can experience large swings in short periods, while low volatility suggests stable prices. Factors causing volatility include market sentiment, earnings announcements, global events, economic indicators, and industry news. High volatility can create opportunities for traders to profit from rapid price changes but also increases risk for long-term investors. Understanding volatility helps investors manage risk, set stop-loss limits, and determine the appropriate investment horizon based on their risk tolerance.

KREBS BIOCHEMICALS & IND

KREBSBIO

Small Cap | Pharmaceuticals

₹66.38

+1.82 (+2.81%)

‌

Stock price as on 23 Jun 2026 at 15:29 PM

Krebs biochemicals & ind share price update

As of the latest trading session, Krebs Biochemicals & Ind share price is currently at ₹66.38, which is up by ₹1.82 from its previous closing. Today t...

Krebs Biochemicals & Ind stock performance

Today’s low

₹64.25

Today’s high

₹66.99

₹66.38

52 week low

₹38.33

52 week high

₹91.9

₹66.38

Open

₹65.70

Previous close

₹64.56

Share volume

4,057

Total traded value (Lakh)

₹2.65

Upper circuit

₹71.01

Lower circuit

₹58.11

Krebs Biochemicals & Ind fundamentals

Market cap (Cr)

₹141.10

P/E ratio (TTM)

-8.16

Book value per share

-₹75.48

Beta

1.09

Return on equity

Earnings per share (TTM)

₹0.00

Dividend yield

Net profit/quarter (Cr)

-₹2.34

Krebs Biochemicals & Ind financials

(Values in Cr)

Revenue

Net income

Particulars	Mar 26 (₹ value in crores)
Revenue	₹6.81
Operating expense	₹11.15
Net income	-₹2.34
Net profit margin	-34.36%
Earning per share	-₹1.09
EBITDA	₹1.14
Effective tax rate	-

Particulars	Dec 25 (₹ value in crores)
Revenue	₹7.27
Operating expense	₹10.39
Net income	-₹3.13
Net profit margin	-43.05%
Earning per share	-₹1.45
EBITDA	₹0.29
Effective tax rate	-

Particulars	Sep 25 (₹ value in crores)
Revenue	₹4.17
Operating expense	₹10.31
Net income	-₹6.14
Net profit margin	-147.24%
Earning per share	-₹2.85
EBITDA	-₹2.79
Effective tax rate	-

Particulars	Jun 25 (₹ value in crores)
Revenue	₹5.48
Operating expense	₹10.82
Net income	-₹5.32
Net profit margin	-97.08%
Earning per share	-₹2.47
EBITDA	-₹2.07
Effective tax rate	-

Particulars	Mar 25 (₹ value in crores)
Revenue	₹6.10
Operating expense	₹14.69
Net income	-₹8.27
Net profit margin	-135.57%
Earning per share	-₹3.83
EBITDA	-₹5.06
Effective tax rate	-0.24%

Particulars	Mar 26 (₹ value in crores)
Revenue	₹23.73
Operating expense	₹42.70
Net income	-₹16.93
Net profit margin	-71.34%
Earning per share	-₹7.85
EBITDA	-₹3.42
Effective tax rate	-

Particulars	Mar 25 (₹ value in crores)
Revenue	₹43.31
Operating expense	₹70.94
Net income	-₹26.94
Net profit margin	-62.2%
Earning per share	-₹12.49
EBITDA	-₹14.32
Effective tax rate	-0.07%

Particulars	Mar 24 (₹ value in crores)
Revenue	₹50.42
Operating expense	₹70.60
Net income	-₹19.73
Net profit margin	-39.13%
Earning per share	-₹9.16
EBITDA	-₹8.27
Effective tax rate	-

Particulars	Mar 23 (₹ value in crores)
Revenue	₹52.13
Operating expense	₹77.44
Net income	-₹24.69
Net profit margin	-47.36%
Earning per share	-₹11.30
EBITDA	-₹15.16
Effective tax rate	-

Particulars	Mar 22 (₹ value in crores)
Revenue	₹59.70
Operating expense	₹105.38
Net income	-₹44.53
Net profit margin	-74.58%
Earning per share	-₹20.81
EBITDA	-₹32.84
Effective tax rate	-

Particulars (annual)	Mar 25 (₹ value in crores)
Book value per share	-₹67.83
Return on Equity (ROE)	-
Return on Capital Employed (ROCE)	-
Total debt to equity ratio	-
EBITDA margin	-33.06%

Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	-₹55.29
Return on Equity (ROE)	-
Return on Capital Employed (ROCE)	-
Total debt to equity ratio	2.83
EBITDA margin	-16.4%

Particulars (annual)	Mar 23 (₹ value in crores)
Book value per share	-₹46.13
Return on Equity (ROE)	-
Return on Capital Employed (ROCE)	-
Total debt to equity ratio	0.78
EBITDA margin	-29.08%

Particulars (annual)	Mar 22 (₹ value in crores)
Book value per share	-₹34.83
Return on Equity (ROE)	-
Return on Capital Employed (ROCE)	-
Total debt to equity ratio	2.23
EBITDA margin	-55.01%

Particulars (annual)	Mar 21 (₹ value in crores)
Book value per share	-₹23.91
Return on Equity (ROE)	-
Return on Capital Employed (ROCE)	-
Total debt to equity ratio	-
EBITDA margin	-31.56%

Particulars	Mar 25 (₹ value in crores)
Cash and short term investments	₹0.14
Total assets	₹169.03
Total liabilities	₹169.03
Total equity	-₹146.23
Shares outstanding	₹2.15
Price to book ratio	-₹0.98
Return on assets (%)	-15.93%
Return on capital	-40.84%

Particulars	Mar 24 (₹ value in crores)
Cash and short term investments	₹0.13
Total assets	₹178.17
Total liabilities	₹178.17
Total equity	-₹119.21
Shares outstanding	₹2.15
Price to book ratio	-₹1.10
Return on assets (%)	-11.07%
Return on capital	-26.58%

Particulars	Mar 23 (₹ value in crores)
Cash and short term investments	₹0.08
Total assets	₹174.98
Total liabilities	₹174.98
Total equity	-₹99.46
Shares outstanding	₹2.15
Price to book ratio	-₹1.22
Return on assets (%)	-14.11%
Return on capital	-29.47%

Particulars	Mar 22 (₹ value in crores)
Cash and short term investments	₹0.10
Total assets	₹189.80
Total liabilities	₹189.80
Total equity	-₹75.09
Shares outstanding	₹2.15
Price to book ratio	-₹4.12
Return on assets (%)	-23.45%
Return on capital	-65.65%

Particulars	Mar 21 (₹ value in crores)
Cash and short term investments	₹0.71
Total assets	₹159.22
Total liabilities	₹159.22
Total equity	-₹42.73
Shares outstanding	₹1.96
Price to book ratio	-₹3.72
Return on assets (%)	-17.81%
Return on capital	-41.82%

Particulars	Mar 25 (₹ value in crores)
Net income	-₹26.92
Cash from operations	-₹7.87
Cash from investing	-₹4.96
Cash from financing	₹12.86
Net change in cash	-
Free cash flow	-₹4.47

Particulars	Mar 24 (₹ value in crores)
Net income	-₹19.72
Cash from operations	₹2.36
Cash from investing	-₹7.81
Cash from financing	₹5.50
Net change in cash	₹0.05
Free cash flow	₹11.77

Particulars	Mar 23 (₹ value in crores)
Net income	-₹24.69
Cash from operations	-₹24.71
Cash from investing	-₹12.64
Cash from financing	₹37.34
Net change in cash	-₹0.01
Free cash flow	-₹9.55

Particulars	Mar 22 (₹ value in crores)
Net income	-₹44.52
Cash from operations	-₹17.21
Cash from investing	-₹22.89
Cash from financing	₹39.50
Net change in cash	-₹0.61
Free cash flow	₹9.86

Particulars	Mar 21 (₹ value in crores)
Net income	-₹28.35
Cash from operations	-₹14.57
Cash from investing	-₹22.54
Cash from financing	₹37.66
Net change in cash	₹0.53
Free cash flow	₹3.18

Company name	Price	P/E	P/B	Market cap	52 week low/high
AMBALAL SARABHAI ENT L	₹31.80	13.14	1.53	₹243.69	₹23.12 / ₹38.85
BLISS GVS PHARMA LTD.	₹486.60	39.5	4.32	₹5,160.70	₹118.35 / ₹493.70
CIPLA LTD	₹1,353.85	28.73	3.17	₹1,09,370.14	₹1,165.55 / ₹1,672.20
FERMENTA BIOTECH LIMITED	₹338.20	14.92	2.44	₹995.36	₹256.40 / ₹399.00
GLAXOSMITHKLINE PHARMA LT	₹2,332.85	41.07	17.42	₹39,519.89	₹2,088.00 / ₹3,500.00

Company name	Price	P/E	P/B	Market cap	52 week low/high
AMBALAL SARABHAI ENT L	₹31.80	13.14	1.53	₹243.69	₹23.12 / ₹38.85
BLISS GVS PHARMA LTD.	₹486.60	39.5	4.32	₹5,160.70	₹118.35 / ₹493.70
CIPLA LTD	₹1,353.85	28.73	3.17	₹1,09,370.14	₹1,165.55 / ₹1,672.20
FERMENTA BIOTECH LIMITED	₹338.20	14.92	2.44	₹995.36	₹256.40 / ₹399.00
GLAXOSMITHKLINE PHARMA LT	₹2,332.85	41.07	17.42	₹39,519.89	₹2,088.00 / ₹3,500.00

Krebs Biochemicals & Ind technical summary

₹65.45

+ 1.37 ▲

Bearish

Bullish

5 Day65.1

10 Day65.1

12 Day65

20 Day64.3

26 Day63.7

50 Day61.9

100 Day61.4

200 Day64.6

Investment Returns

Over 1 Month13.24%▲

Over 3 Months37.91%▲

Over 6 Months5.54%▼

Over 1 Year25.43%▼

Krebs Biochemicals & Ind Shareholding pattern

Public

26.75%

Promoter holdings

72.74%

FII

0.49%

DII

Promoter shares

Promoter shares	Share	Category
Ipca Laboratories Limited	1,07,05,195 (49.65%)	Shareholding of Promoter and Promoter Group
Hemalatha Ravi	26,91,524 (12.48%)	Shareholding of Promoter and Promoter Group
Avinash Ravi	21,40,272 (9.93%)	Shareholding of Promoter and Promoter Group
Sun Pharmaceutical Industries Ltd	10,36,943 (4.81%)	Public Shareholding
Ajay Ravi	1,12,997 (0.52%)	Shareholding of Promoter and Promoter Group

About KREBS BIOCHEMICALS & IND

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991. The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003. Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards. Production of two new products has commenced in the Nellore unit of the company during 2008. The sales from Unit II showed a healthy increase and small activity started in Unit I through Contract Manufacturing in 2010-11. The steep drop in income was attributed to discontinuing of Lovastatin manufacturing from April, 2012 in Unit ll. Starting from April 2012, the power supply was restricted the Andhra Pradesh government making it unviable and impractical to run the manufacturing of Lovastatin. Further, this affected the manufacturing of Simvastatin for which Lovastatin as the key raw material. Unit 2 due to the power shortage became sick in 2012. The Company undertook a financial restructuring to revive the operations in 2013. Ipca Laboratories Limited acquired 31.38% stake in the Company, making it an associate Company during FY15. During the year 2015-16, complete repairs and maintenance of both plants were undertaken to make plants ready for operations after the long shutdown. Some modernisation works were undertaken to meet the latest pollution control norms and safety regulations. All relevant licences were renewed. All the pending statutory requirements were addressed. Products range for both plants was established. Scale up operations including technology sourcing/development, pilot plant trials and validation trails for the identified products began in 2016. During the FY 2019-20, A total of four products were produced in its plant including Phenylephrine HCl, Simvastatin, Serratiopeptidase and RSS. The Vizag manufacturing facility of the Company started manufacturing few drug intermediates in 2023. The manufacturing operations at the Company's Vizag manufacturing unit remained closed since 9th February 2025 pursuant to order issued by Andhra Pradesh Pollution Control Board.

Parent Organisation

Indian Private

NSE Symbol

KREBSBIO

Founded

1991

KREBS BIOCHEMICALS & IND CORPORATE ACTION

No data available.

View more stocks

sun pharmaceutical industries

₹1,868

▲ 0.27%

divi s laboratories ltd

₹6,751.5

▼ 0.53%

torrent pharmaceuticals ltd.

₹4,524

▲ 1.50%

cipla ltd

₹1,433.1

▲ 1.22%

zydus lifesciences ltd

₹1,112.2

▲ 2.45%

dr. reddy s laboratories

₹1,301.3

▲ 0.82%

lupin limited

₹2,357.8

▲ 0.76%

What’s trending

All stocks

SLONE

SLONE INFOSYSTEMS LIMITED

151.2

+25.2 (+20%)

ORBTEXP

ORBIT EXPORTS LIMITED

ORBIT EXPORTS LTD.

PRABHHANS INDUSTRIES LIMITED

46.34

+7.72 (+19.99%)

View all

Top gainers

CIPLA LTD

DR. REDDY S LABORATORIES

1301.3

+10.60 (+0.82%)

POWERGRID

POWER GRID CORP. LTD.

AXIS BANK LIMITED

Top losers

INFOSYS LIMITED

TATA CONSULTANCY SERV LT

2059.6

-68.20 (-3.21%)

ADANIENT

ADANI ENTERPRISES LIMITED

WIPRO LTD

Frequently asked questions

 As of 23/06/2026, at 15:29 PM, the Krebs Biochemicals & Ind share price stands at ₹66.38.

Related tags

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Broking services offered by Bajaj Financial Securities Limited (Bajaj Broking). Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403.

Details of Compliance Officer: Mr. Boudhayan Ghosh (For Broking/DP/Research) | Email: compliance_sec@bajajbroking.in | Contact No.: 020-4857 4486. For any investor grievances write to compliance_sec@bajajbroking.in/ compliance_dp@bajajbroking.in (DP related)

This content is for educational purpose only. Securities quoted are exemplary and not recommendatory.

Research Services are offered by Bajaj Broking as Research Analyst under SEBI Regn: INH000010043.

For more disclaimer, check here: https://www.bajajbroking.in/disclaimer

KREBS BIOCHEMICALS & IND

Krebs biochemicals & ind share price update

Krebs Biochemicals & Ind stock performance

₹64.25

₹66.99

₹38.33

₹91.9

Krebs Biochemicals & Ind fundamentals

Krebs Biochemicals & Ind financials

Particulars

Mar 26 (₹ value in crores)

Revenue

₹6.81

Operating expense

₹11.15

Net income

-₹2.34

Net profit margin

-34.36%

Earning per share

-₹1.09

EBITDA

₹1.14

Effective tax rate

-

Particulars

Dec 25 (₹ value in crores)

Revenue

₹7.27

Operating expense

₹10.39

Net income

-₹3.13

Net profit margin

-43.05%

Earning per share

-₹1.45

EBITDA

₹0.29

Effective tax rate

-

Particulars

Sep 25 (₹ value in crores)

Revenue

₹4.17

Operating expense

₹10.31

Net income

-₹6.14

Net profit margin

-147.24%

Earning per share

-₹2.85

EBITDA

-₹2.79

Effective tax rate

-

Particulars

Jun 25 (₹ value in crores)

Revenue

₹5.48

Operating expense

₹10.82

Net income

-₹5.32

Net profit margin

-97.08%

Earning per share

-₹2.47

EBITDA

-₹2.07

Effective tax rate

-

Particulars

Mar 25 (₹ value in crores)

Revenue

₹6.10

Operating expense

₹14.69

Net income